Document is current
Any future updates will be listed below
-
Authors
Elmeliegy, Mohamed https://orcid.org/0000-0002-9825-5890
Viqueira, Andrea
Vandendries, Erik
Hickman, Anne
Conte, Umberto
Irby, Donald
Hibma, Jennifer
Lon, Hoi-Kei
Piscitelli, Joseph
Soltantabar, Pooneh
Skoura, Athanasia
Jiang, Sibo
Wang, Diane
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03269136 at ClinicalTrials.govnct04798586 at ClinicalTrials.govDocuments that mention this clinical trial
Molecular features and outcomes for patients receiving elranatamab for relapsed or refractory multiple myeloma in MagnetisMM-1.
https://doi.org/10.1200/jco.2023.41.16_suppl.e20021
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma
https://doi.org/10.1136/jitc-2020-000734
Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.
https://doi.org/10.1200/jco.2023.41.16_suppl.8008
Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology
https://doi.org/10.1136/jitc-2021-004225
Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma
https://doi.org/10.1007/s11523-025-01134-8
nct04649359 at ClinicalTrials.govDocuments that mention this clinical trial
Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma
https://doi.org/10.1007/s11523-025-01134-8
nct05014412 at ClinicalTrials.govDocuments that mention this clinical trial
Efficacy and safety of elranatamab in patients with high-risk relapsed/refractory multiple myeloma (RRMM): A subgroup analysis from MagnetisMM-3.
https://doi.org/10.1200/jco.2023.41.16_suppl.e20017
Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed/refractory multiple myeloma (RRMM): Extended follow up and biweekly administration from the MagnetisMM-3 study.
https://doi.org/10.1200/jco.2023.41.16_suppl.8039
Identification of cytokines associated with response and cytokine release syndrome: Analysis of MagnetisMM-3 cohort A.
https://doi.org/10.1200/jco.2023.41.16_suppl.8044
Efficacy and safety of elranatamab by age and frailty in patients (pts) with relapsed/refractory multiple (RRMM): A subgroup analysis from MagnetisMM-3.
https://doi.org/10.1200/jco.2023.41.16_suppl.8040
Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.
https://doi.org/10.1200/jco.2023.41.16_suppl.8008
Genomic analysis to identify determinants of inherent response and resistance to elranatamab in MagnetisMM-3 cohort A.
https://doi.org/10.1200/jco.2023.41.16_suppl.8045
Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma
https://doi.org/10.1007/s11523-025-01134-8
Documents that mention this clinical trial
Evaluation of cytokine release syndrome (CRS) in patients with relapsed or refractory multiple myeloma (RRMM) receiving step-up priming doses and longer dosing intervals of elranatamab: MagnetisMM-9.
https://doi.org/10.1200/jco.2024.42.16_suppl.7522
Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MagnetisMM studies.
https://doi.org/10.1200/jco.2023.41.16_suppl.8008
Dose Optimization of Elranatamab to Mitigate the Risk of Cytokine Release Syndrome in Patients with Multiple Myeloma
https://doi.org/10.1007/s11523-025-01134-8
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Accepted: 11 February 2025
First Online: 25 February 2025
Declarations
:
: This study was funded by Pfizer.
: Mohamed Elmeliegy, Andrea Viqueira, Erik Vandendries, Anne Hickman, Umberto Conte, Donald Irby, Jennifer Hibma, Hoi-Kei Lon, Joseph Piscitelli, Pooneh Soltantabar, Athanasia Skoura, Sibo Jiang, and Diane Wang report employment and stock ownership at Pfizer.
: All studies reported here were conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization guidelines for Good Clinical Practice. The study protocols and relevant documents were approved by independent institutional review boards or ethics committees at each investigative center.
: All patients provided written informed consent.
: Not applicable.
: Upon reasonable request and subject to review, Pfizer will provide the data that support the findings of this article. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See for more information.
: Not applicable.
: All authors were involved in the trial conception/design, or the acquisition, analysis, or interpretation of data. All authors contributed to the drafting of the manuscript and approved the final version.
